Julius Knowles
Director/Board Member at KEROS THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alon Lazarus | M | 49 |
Paros Bio, Inc.
 Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | 5 years |
| Carl Gordon | M | 59 | 4 years | |
| Stephen R. Lewis | M | 85 |
Carleton College
| 42 years |
| Carl Berke | M | - |
Mass General Brigham Ventures LLC
 Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts. | 18 years |
| Jasbir Seehra | M | 68 | 9 years | |
| Ran Nussbaum | M | 51 | 8 years | |
| Stefano Gulla | M | - |
Abcuro, Inc.
 Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Alpna Seth | M | 60 | 1 years | |
| Esther Cho | F | - | 4 years | |
| Jennifer Lachey | M | 51 | 8 years | |
| Mary Gray | M | 71 | 4 years | |
| Nima Farzan | M | 48 | 4 years | |
| Tomer Kariv | M | 62 | 4 years | |
| Nalan Utku | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Elizabeth E. Bailey | F | 86 |
University of Pennsylvania
| 33 years |
| Ryan Berry | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | 3 years |
| Donald McCarthy | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | 2 years |
| Darlene Deptula-Hicks | F | 66 |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | 3 years |
| Anna Phil | M | 36 |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | - |
| Stuart Russell | M | - |
University of California, Berkeley
| 38 years |
| Jorge Escobar | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Ya Jun Xu | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Robin Wagner | F | - | 3 years | |
| Kathryn Swiderski | F | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | - |
| Kees Been | M | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | - |
| Sourav Kole | M | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | 2 years |
| Ruoxi Hu | F | - |
Mass General Brigham Ventures LLC
Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts. | - |
| Christopher Rovaldi | M | 50 | 2 years | |
| Kenneth Evan Thompson | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Robert A. Millman | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Ira R. Harkavy | M | 75 |
University of Pennsylvania
| 32 years |
| Stacey Brenner | F | - |
Mass General Brigham Ventures LLC
Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts. | 8 years |
| Amir Nashat | M | 51 |
Partners Innovation Fund LLC
 Partners Innovation Fund LLC Investment ManagersFinance Partners Innovation Fund LLC, an Evergreen Fund, invests in companies located in the US. The fund targets companies operating in the fields of healthcare sector. It provides financing for seed and early stage capital requirements. It also makes follow on investments. | - |
| Roger D. Kitterman | M | - |
Mass General Brigham Ventures LLC
Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts. | 17 years |
| Alex Martin Martin | M | 55 |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Jeffrey Ostrove | M | - |
Paros Bio, Inc.
Paros Bio, Inc. BiotechnologyHealth Technology Paros Bio, Inc. is a company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. Specifically, they are developing a gene replacement approach to treat autosomal dominant Alzheimer's disease caused by mutations in the presenilin 1 gene. The company's therapy directly addresses the underlying genetic cause of the disease. | - |
| Marc K. Hellerstein | M | 72 |
University of California, Berkeley
| 37 years |
| Ya Jun Xu | M | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | - |
| Iyona Rajkomar | F | - |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | 3 years |
| Keith Regnante | M | 54 | 4 years | |
| Robert J. Borghese | M | - |
University of Pennsylvania
| 32 years |
| Donald A. McQuade | M | 82 |
University of California, Berkeley
| 38 years |
| Meredith Fisher | M | - |
Mass General Brigham Ventures LLC
Mass General Brigham Ventures LLC Investment ManagersFinance Mass General Brigham Ventures LLC (Mass General Brigham Ventures) is a venture capital subsidiary of Partners Research Ventures & Licensing founded in 2005. The firm is headquartered in the Cambridge, Massachusetts. | 8 years |
| Jason Hafler | M | 42 |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | 3 years |
| Justin Frantz | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Vurgait | M | 59 |
University of Pennsylvania
| 1 years |
| Ori Sasson | M | - |
University of California, Berkeley
| 6 years |
| Kenneth Robert Marcus | M | - |
University of Pennsylvania
| 5 years |
| Ana Dolores Moura Carneiro de Novaes | M | 62 |
University of California, Berkeley
| 4 years |
| Juan Pablo Córdoba Garcés | M | - |
University of Pennsylvania
| 5 years |
| Fabio Ignazio Romeo | M | 68 |
University of California, Berkeley
| 4 years |
| Pierre Breber | M | 59 |
University of California, Berkeley
| 5 years |
| Ze Xiang Li | M | 63 |
University of California, Berkeley
| 4 years |
| Brant Binder | M | - |
X-Body, Inc.
 X-Body, Inc. BiotechnologyHealth Technology X-BODY, Inc. provides biotechnological research services. The company was founded on April 9, 2009 and is headquartered in Waltham, MA. | 3 years |
| Alex Abell | M | - |
University of Pennsylvania
| 4 years |
| Jeffrey L. Streator | M | 60 |
University of California, Berkeley
| 5 years |
| Tom G. Rock | M | - |
Carleton College
| 4 years |
| Mark C. Holscher | M | - |
University of California, Berkeley
| 7 years |
| Helen Remeza | M | - |
University of Pennsylvania
| 5 years |
| Christoph S. Lengauer | M | 59 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | 3 years |
| Darius Beni Cayetano | M | 50 |
University of Pennsylvania
| 11 years |
| Rich Ballew | M | - |
University of Pennsylvania
| 3 years |
| Gregory Z. Rush | M | - |
University of Pennsylvania
| 4 years |
| David Anderman | M | - |
University of Pennsylvania
| 4 years |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 6 years |
| Jaideep Srivastava | M | - |
University of California, Berkeley
| 4 years |
| Matthew B. Hemington | M | - |
University of California, Berkeley
| 8 years |
| Weijie Yun | M | 60 |
University of California, Berkeley
| 5 years |
| Henry Skinner | M | 60 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | 2 years |
| Richard H. Aldrich | M | 69 | 12 years | |
| Thomas G. Auchincloss | M | 62 | 7 years | |
| Paul Jacobs | M | 61 |
University of California, Berkeley
| 4 years |
| David Choi | M | - |
University of California, Berkeley
| 5 years |
| Joan Midthun Larrea | F | 58 |
University of Pennsylvania
| 4 years |
| Lisa Suennen | F | 58 |
University of California, Berkeley
| 5 years |
| Thomas B. Ottoboni | M | 65 |
University of California, Berkeley
| 7 years |
| Fabio Romeo | M | - |
University of California, Berkeley
| 4 years |
| Greg Brogger | M | 55 |
University of California, Berkeley
University of Pennsylvania
| 9 years |
| Steve B. Baus | M | 58 |
University of California, Berkeley
University of Pennsylvania
| 7 years |
| Robert Yung | M | 61 |
University of California, Berkeley
| 6 years |
| William Michael Kavanaugh | M | 67 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | 3 years |
| Thomas E. Tighe | M | - |
University of California, Berkeley
| 7 years |
| Richard E. Fearon | M | 58 |
University of Pennsylvania
| 2 years |
| Parag A. Majmudar | M | - |
University of Pennsylvania
| 4 years |
| Lynn Loo | M | - |
University of Pennsylvania
| 4 years |
| Derek Goodman | M | - |
University of Pennsylvania
| 4 years |
| Bill Hassiepen | M | - |
University of Pennsylvania
| 9 years |
| Walid Mouawad | M | - |
University of Pennsylvania
| 4 years |
| Jason Adelman | M | 55 |
University of Pennsylvania
| 4 years |
| Jon Holtaway | M | 53 |
University of Pennsylvania
| 4 years |
| Lara Leibman | F | - |
University of Pennsylvania
| 4 years |
| Brett Patelsky | M | - |
University of Pennsylvania
| 4 years |
| Woody Anderson | M | - |
University of Pennsylvania
| 4 years |
| Kassy Kebede | M | 67 |
University of Pennsylvania
| 2 years |
| Katinka Ildiko Domotorffy | F | 49 |
University of Pennsylvania
| 4 years |
| Jonathan Brolin | M | 51 |
University of Pennsylvania
| 4 years |
| Charles C. Pak | M | - |
University of Pennsylvania
| 4 years |
| Yann S. Souillard | M | 55 |
University of Pennsylvania
| 3 years |
| Ge Ruowen | M | - |
University of Pennsylvania
| 3 years |
| Michelle Werner | F | - |
University of Pennsylvania
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 99.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Julius Knowles
- Personal Network
